Madrigal Pharmaceuticals, Inc. MDGL
$499.41
▲ +1.37% 24H
About
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and related liver conditions. Its lead product, Rezdiffra (resmetirom), is a li…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees915
TickerMDGL
Statistics
Market Cap$11.51B
Revenue (TTM)$958.4M
Net Income-$288.3M
Net Margin-30.1%
EPS$-12.85
P/E-37.43
P/S9.66
P/B20.11
EV/EBITDA-33.34
ROE-49.3%
Dividend Yield—
Price$499.41
Data: Twelve Data · Revenue = mcap / P/S